

5 **REVIEW**

7 **Bacteriology of Wound Infections in Nigeria and its Effect**
8 **on Antibiotics Selection during Management**

10 **Chukwu E E.^{1*}, Fadunsin, F A.¹, Nwaokorie F O.²**

11 ¹Centre for Infectious Diseases Research, Microbiology Department, Nigerian Institute of Medical
12 Research Yaba, Lagos, Nigeria.

13 ²Department of Medical Laboratory Sciences, College of Medicine, University of Lagos, Nigeria

15 Correspondence: Dr. Emelda Chukwu; Email: emeldachukwu123@gmail.com

17 **ABSTRACT**

18 A wound is a rupture in the skin exposing the underlying subcutaneous tissue. It creates a moist,
19 warm, and nutritive environment conducive to microbial colonization and proliferation.
20 Depending on the time it takes for the wound to heal, it can be categorized as either acute or
21 chronic. Infection in a wound elongates the healing period and results in longer hospital stays
22 and higher treatment costs. Most open wound infections are polymicrobial containing both
23 aerobic and anaerobic microorganisms, which should be considered when choosing
24 antimicrobials. Controlling wound infections has become more difficult as the prevalence of
25 antibiotic resistance has increased. This problem is exacerbated in Nigeria by a lack of
26 epidemiological data on the microbial agents that cause wound infections. Thus, it is necessary
27 to understand the microbes prevalent in infected wounds to encourage proper antimicrobial
28 selection for the offending microbe and enhance better treatment and management outcomes.
29 The bacteriology of wound infections, susceptibilities to routinely prescribed antibiotics, and
30 the effects of the presence of these bacterial species in wound management are all discussed in
31 this review.

33 **Keywords:** Wound infection; Microbial colonization; Polymicrobial infection; Antibiotic
34 resistance; Aerobes; Anaerobes

35 **1. INTRODUCTION**

36 Wound infections continue to be a source of concern in clinical practice as they cause delayed
37 or poor wound healing. In 2010, the World Health Organization (WHO) reported that the
38 prevalence of healthcare-associated wound infections in low-income and middle-income
39 countries (LMICs) was 2 to 20 times higher than in high-income countries [1,2]. Surgical site
40 infection (SSI) was the most frequently reported and surveyed infection affecting up to one-
41 third of patients who underwent surgery. SSI is the second leading cause of healthcare-
42 associated infection in Europe and the United States [1,3]. According to data from the USA,
43 up to 60% of the microorganisms isolated from infected surgical wounds are antibiotic-resistant
44 [4]. In Nigeria, the incidence of SSI has been documented in parts of the country [5,6,7].
45 Olowo-okere et al. [7] have reported an incidence of 27.6% in a Tertiary Healthcare Facility in
46 Abuja, Nigeria. Prolonged postoperative hospital stays, wound type, and several comorbidity
47 conditions were all shown to be associated with a higher SSI rate.

48 Infected wounds are home to various microorganisms, including Gram-positive cocci such as
49 *Staphylococcus aureus* and *Streptococcus* spp.; Gram-negative bacilli, mostly *Acinetobacter*,
50 *Enterobacter*, *E. coli*, *Proteus* spp., and *P. aeruginosa*; anaerobic bacteria, especially
51 *Clostridium* spp., *Propionibacterium* spp., and *Bacteroides* spp. [8,9]. These wound pathogens
52 produce several virulence factors that mediate adhesion, nutrient acquisition, immune system
53 evasion, leukocyte killing, tissue destruction, and bloodstream invasion [10].

54 Despite significant technological breakthroughs in the management of wound infections, it
55 remains the most prevalent nosocomial infection in patients undergoing surgery [11,12].
56 Lifestyle diseases, such as diabetes, obesity, and cardiovascular diseases, contribute
57 significantly to the yearly proportion of chronic wound infections [13]. In 2011, 366 million
58 individuals worldwide were diagnosed with diabetes, which is projected to rise to 552 million
59 by 2030 [14]. In addition, nearly 80% of people with diabetes reside in low- and middle-income
60 countries, including Nigeria. Polymicrobial infections make up the majority of wound
61 infections, and microbial synergy increases the severity of infection in several ways. Oxygen
62 consumption by aerobic bacteria induces tissue hypoxia and reduces the redox potential, which
63 promotes anaerobic bacteria growth. Specific nutrients produced by one bacterium may
64 encourage the growth of fastidious and potentially pathogenic cohabiting microorganisms, and
65 some anaerobes can interfere with the operations of the host's immune cell function. As a
66 result, they gain a competitive advantage for themselves and other cohabiting microorganisms
67 [15,16].

68 Bacterial resistance to medications has made controlling wound infections more difficult,
69 particularly in infections caused by methicillin-resistant *Staphylococcus aureus* (MRSA) and

70 polymicrobial flora [12,17]. In addition to the direct care of patients, diagnostic microbiology
71 findings are utilized to inform local, regional, and national surveillance systems. As a result,
72 WHO recommends laboratory-based antibiotic resistance surveillance [18]. The scarcity of
73 quality-assured microbiology laboratories in low-resource settings and the minimal attention
74 given to persistent bacterial surveillance have resulted in a shortage of resistance data,
75 particularly in sub-Saharan Africa and rural Asia [19]. This review aims to explore current
76 views on diverse wound infections, compare their etiology, and assess the microbiologist and
77 the microbiology laboratory's role in diagnosing and treating microbial colonization and
78 infection in wounds.

79

80 **2. WOUND INFECTIONS**

81 The fundamental role of healthy, undamaged skin is to keep microbial populations that live on
82 the skin surface under control and to prevent possible pathogens from colonizing and invading
83 underlying tissue [15,20]. A wound causes a breach in the skin, exposing subcutaneous tissue
84 and causing skin integrity to be compromised. This creates a moist, warm, and nutrient-rich
85 environment that encourages microbial colonization and proliferation [16]. Depending on how
86 long it takes for a wound to heal, it can be classified as acute or chronic [17,21]. Infected
87 wounds take longer to heal and lengthen hospital stays. Furthermore, the overall cost of wound
88 management rises significantly when infected [9,15].

89 Infection occurs when virulence factors expressed by microorganisms in a wound overcome
90 the host's natural immune system and subsequently invade and disseminate viable
91 microorganisms into the tissues, thereby triggering a cascade of local and systemic host
92 responses [15,22]. A variety of microbial and host factors contribute to the wound being
93 infected. The wound's type, location, size, and depth all play a role in these reactions. Other
94 factors include the degree of blood perfusion to the wound, the host's overall health and
95 immunological condition, the microbial load, and the combined level of virulence displayed by
96 the types of bacteria [15]. Most acute and chronic wound infections are caused by a
97 combination of aerobic and anaerobic bacteria [23]. In numerous investigations, the most
98 prevalent wound isolates were *Staphylococcus aureus* and *Pseudomonas aeruginosa*, which
99 may be found in both healing and nonhealing wounds [24,25].

100 Burn wounds, surgical sites, bite wounds, acute soft tissue infections, diabetic foot ulcers, and
101 leg and pressure ulcer infections are all examples of wound infections. However, SSIs are the
102 most common type of healthcare-associated infections, leading to increased patient morbidity
103 and death, particularly in low-resource countries [1]. As a result, the WHO guideline

104 development group was formed and charged with the responsibility of developing a guideline
105 for the prevention of SSI. They came up with 29 recommendations and key measures for SSI
106 prevention to be implemented in the preoperative, intraoperative, and postoperative periods
107 [26,27]. These recommendations were developed from a global perspective, taking into
108 account the balance of benefits and risks, the quality of evidence, cost and resource
109 implications, and patient values and preferences. Similarly, in 1999, the Centers for Disease
110 Control and Prevention (CDC) issued broad recommendations for preventing surgical
111 infections, which were reviewed and revised in 2017 [28]. If these guidelines are followed
112 consistently, the risk of surgical infections may be significantly reduced.

113 **2.1 Bacteriological profile of wound infections in Nigeria**

114 Most wound pathogens are bacteria, and the etiology of wound infection in Nigeria follows a
115 similar trend as in other countries [22]. In Nigeria, wound infection analysis has revealed
116 various findings across different areas and states, emphasizing the need for local prevalence
117 and susceptibility investigations. Despite this, studies have repeatedly shown that *S. aureus*, *P.*
118 *aeruginosa*, and *Proteus* species are the most common bacteria found in wound infections in
119 Nigeria [21,22,29]. There has also been evidence of polymicrobial infection involving both
120 aerobic and anaerobic bacteria [30,31]. Unfortunately, most studies in Nigeria on the microbial
121 profile of wound infections focus on aerobic species, leaving data on anaerobic organisms
122 capable of causing severe infections leading to sepsis, lacking. Regardless of the types and
123 nature of wounds, *Staphylococcus aureus* is the most commonly identified Gram-positive
124 bacterium from diverse wound infections in Nigeria [23,29,31,32]. *Staphylococcus aureus* was
125 found to be most susceptible to amikacin (83%) and erythromycin (79 %) and least sensitive
126 to amoxicillin (53 %), clindamycin (55 %), and cefuroxime (55 %) in research by Iroegbu et
127 al. [22]. However, Saini and workers [23] have reported that the most effective antibiotics for
128 *S. aureus* were clindamycin, amikacin, and cefuroxime. Nasal carriage of *S. aureus* has been
129 established as a significant risk factor for infection [20,33]. The proposed sequence of events
130 comprises nasal carriage, which is subsequently spread to other body regions via hand carriage,
131 where infection can develop through cracks in the dermal surfaces [33]. On the other hand,
132 concurrent studies have identified *Pseudomonas aeruginosa* [30], *Proteus* spp. [34], and
133 *Klebsiella* [35] as the most common Gram-negative organisms in various wound infections.
134 Recent studies have also reported this trend in other West African countries [36,37]. Analysis
135 of chronically infected wounds in a rural district hospital in Ghana revealed a predominance of
136 *Enterobacteriaceae* (41%), mainly *P. aeruginosa*, and *Staphylococcus aureus* (14%) as
137 predominant Gram-positive bacteria [36].

138 *Pseudomonas aeruginosa* is notorious for its antibiotic resistance due to the permeability
139 barrier afforded by its Gram-negative outer membrane. Also, its tendency to colonize surfaces
140 in a biofilm form makes the cells impervious to therapeutic concentrations of antibiotics. Thus,
141 *P. aeruginosa* was resistant to six antibiotics (amoxicillin, erythromycin, cotrimoxazole,
142 gentamycin, streptomycin, and Zinacef) out of 10 employed in research on diabetic wound
143 infection [29]. Similarly, Iroegbu and colleagues stated that *Pseudomonas aeruginosa* was
144 most responsive to imipenem and amikacin and least sensitive to gentamicin, ceftazidime, and
145 ofloxacin in a research on wound infections in Abuja, Nigeria. [22] (see Table 1). This tendency
146 is not unique to Nigeria; a similar trend has been recorded in the United States [38], Europe
147 [9], and Asia [16]. A comprehensive review and meta-analysis in the UK identified *P.*
148 *aeruginosa*, *K. pneumoniae*, *E. coli*, *Enterobacter* spp., and *Proteus* spp. as the most prevalent
149 Gram-negative organisms isolated from infected burn wounds [9]. Using microarray and next-
150 generation sequencing, numerous *Pseudomonas* species were discovered in tissue biopsies
151 from combat wound samples in US service members [38]. Furthermore, *P. aeruginosa*, *P.*
152 *entomophila*, *P. putida*, and *P. stutzeri* were among the isolates.

153 *Proteus mirabilis* is the species most commonly recovered from the urinary tract and wound
154 infections. It is responsible for 90% of all illnesses caused by the *Proteus* genus [39]. Mordi
155 and Momoh [32] conducted a two-year prospective investigation at the University of Benin
156 Teaching Hospital and found that 390 (97.5%) of the 400 wound samples from diverse areas
157 of the body showed growth of *Proteus* species accounting for 150 (26.8%) of the isolates.
158 *Proteus mirabilis* was the most often isolated *Proteus* species (97.3%), followed by *Proteus*
159 *vulgaris* (40.7%), *Proteus rettgeri* (8.40%), and *Proteus morgagni* (5%). Amikacin (100%)
160 and imipenem (78%) were the most effective antibiotics against *Proteus* species, whereas
161 amoxicillin/clavulanate and cefuroxime were the least effective [22]. Unfortunately, isolation
162 and identification of anaerobes are time-consuming and expensive, particularly in developing
163 countries, and only a few laboratories routinely or even periodically test for clinical anaerobic
164 species [40]. Bacteroides were found to be the most common anaerobe species [30]. A
165 summary of the bacteria species found in wound infections in Nigeria is shown in Table 1.

166 **2.2 Risk factors of wound infections**

167 Wound infections remain a major clinical challenge for hospitals, especially in developing
168 countries where limited resources weigh down adequate healthcare delivery. Studies have
169 implicated several risk factors for acute and chronic wound infections, including older age,
170 diabetes, immune system disorders, cancer, HIV infection, malnutrition, paralysis (limited
171 mobility), and hospitalization, which increases the risk of infection by organisms that are

172 resistant to antibiotics [44,45]. Several studies have attested that various risk factors come into
173 play in wound infection and reiterate the need for doctors to adhere to aseptic procedures when
174 dealing with surgical wounds [44-46]. Power and colleagues [45] used multivariate logistical
175 regression to reveal that obese patients and those having open surgery had the highest risk of
176 infections in patients who had colorectal surgery. Similarly, a systematic review of risk factors
177 associated with SSI by Korol et al. [47] identified comorbidities, advanced age, risk indices,
178 patient frailty, and surgery complexity as risk factors consistently associated with SSI.
179 Nonetheless, a recent study has reported that surgical treatment, prolonged hospitalization,
180 tracheostomy, pressure ulcer, and previous hospitalization are significant risk factors for
181 MRSA infection in a tertiary care hospital in India [46].

182 On the other hand, sub-Saharan Africa has shown a peculiar trend, with a study reporting lack
183 of constant water supply and breakdown of sterilization equipment as risk factors for the high
184 rate of wound infection in healthcare facilities in Buea, Cameroon [48]. According to this study,
185 age, gender, and wound type were not significant risk factors for wound infection [48]. On the
186 contrary, a meta-analysis of postoperative wound infections returned that male gender and
187 immunosuppression were significantly associated with higher infection rates in patients [49].
188 A study in Northwestern Nigeria has reported age, anemia, obesity, number in operating rooms,
189 and duration of surgery to be significantly associated with SSI levels [50]. This finding agrees
190 with other authors across the globe; however, risk factors appear to differ slightly based on
191 wound type. In another study in Southwestern Nigeria, the authors concluded that patients with
192 HIV infection, diabetes mellitus, preoperative anemia, and chorioamnionitis have an increased
193 risk of postcesarean wound infection [51]. This emphasizes the importance of effective
194 infection control measures and adopting good regular surveillance to reduce the risk of SSI.
195 Although several reports have implicated diverse risk factors for different wound infections,
196 most of these reports have pointed to the fact that people who are less fit (immunosuppressed)
197 with prolonged hospital exposure are at greater risk of wound infection.

198

199 **3. ANTIBIOTIC SELECTION IN WOUND INFECTION MANAGEMENT**

200 Early detection and fast implementation of antimicrobial treatments are essential for the early
201 clearance of infected wounds. Systemic antibiotics are the treatment of choice for infected
202 spreading wounds [9,52]; however, therapeutic dosages may not be obtained in the wound bed
203 in wounds with inadequate blood supply, such as pressure and leg ulcers [9]. In suspected or
204 established wound infection, WHO recommends intravenous penicillin G and metronidazole
205 to be administered every 6 hours and 8 hours, respectively, for 5–7 days [53]. In polymicrobial

206 illnesses, this combination treatment is intended to address both aerobic and anaerobic
207 microorganisms. In contaminated operations, prophylactic antibiotics are also recommended.
208 Unfortunately, in Nigeria, most studies on the microbial profile of wound infections and their
209 antibiotic sensitivity focus on aerobic species; thus, data on critical anaerobic players are
210 severely lacking. Saini and workers [23] recommended using metronidazole, chloramphenicol,
211 or clindamycin to treat anaerobic infections and third-generation cephalosporins, amikacin, and
212 ciprofloxacin for Gram-negative aerobes (*K. pneumonia*, *E. coli*, and *Proteus* spp.) and
213 clindamycin or cefuroxime for *S. aureus*. Newer antibiotic families, such as ureidopenicillin,
214 carbapenems, and b-lactam/b-lactamase inhibitor combinations, have broadened the treatment
215 options for both preventive and therapeutic purposes [23]. Mordi and Momoh [32] have
216 recommended using fluoroquinolones and gentamycin as the antibiotics of choice in wound
217 infections since they are effective and provide the most coverage. Furthermore, Akinjogunla
218 and colleagues [21] have discovered that isolates from car accident wounds were highly
219 susceptible to ofloxacin (81.6%), ciprofloxacin (75.8%), and pefloxacin (81%) but resistant to
220 penicillin, streptomycin, and gentamycin (Table 2). Mupirocin was found to be successful in
221 eradicating *S. aureus* nasal carriage and decreasing SSIs in certain trials [20,54].
222 Most isolates from four general hospitals in Niger State's Bida, Kontagora, Minna, and Suleja
223 districts were susceptible to ciprofloxacin, pefloxacin, and Tarivid, with *S. aureus* displaying
224 a greater resistance profile to most antibiotics utilized than *Streptococcus pyogenes* [55].
225 However, a later examination of infected surgical wounds from patients at Ibrahim Badamasi
226 Babangida specialist hospital in Minna, Niger state, showed a varied report [6]. Among the
227 Gram-negative bacteria isolates, *Klebsiella ozaenae* had the greatest susceptibility to the
228 antibiotics used, whereas *Clostridium perfringens* had the highest sensitivity to the antibiotics
229 used among the Gram-positive bacteria isolates.
230 Despite this, Iroegbu and colleagues discovered an intriguing susceptibility pattern of *S. aureus*
231 to chloramphenicol (100%), a drug seldom used due to its toxicity in the bone marrow and
232 newborns [22]. They concluded that this medicine might be beneficial again in the context of
233 rising multidrug resistance. Even though chloramphenicol has recognized side effects, it has
234 been used increasingly in recent years due to the rise of antibiotic resistance [56]. Most of these
235 ancient antibiotic compounds, such as chloramphenicol, have remained active against many
236 currently widespread bacterial isolates due to low usage levels. Application of a single dose of
237 topical chloramphenicol to high-risk sutured wounds after minor surgery resulted in a
238 significant reduction in infection rate [57] in a prospective randomized placebo-controlled
239 double-blind, multicenter trial. Using topical antibiotics as prophylaxis in preventing SSIs,

240 rather than systemic antibiotics, has been shown to be effective. Various surgical procedures,
241 including joint arthroplasty, cataract surgery, and even breast augmentation [58], have been
242 found to benefit from perioperative topical prophylaxis to reduce postoperative SSI.
243 Cephalosporins, aminoglycosides, glycopeptides, chloramphenicol, and bacitracin [58] are
244 among the most commonly used topical antibiotics. However, the evidence for using topical
245 antibiotics in surgery is still debatable, with no clear randomized controlled studies. As a result,
246 WHO does not recommend their usage.

247 In light of the rising frequency of antibiotic resistance, the WHO advisory committee has
248 recommended a new therapeutic intervention approach [59] instead of antibiotic therapy.
249 Several in vitro investigations have shown that bacteriophages can lyse specific bacterial
250 pathogens [60]. Bacteriophages are bacteria-infecting viruses that are obligate intracellular
251 parasites that replicate within the host via the host's enzymatic machinery. Bacteriophages have
252 a high level of host specificity, infecting only certain strains even within a single bacterial
253 species, whereas some bacteriophages may infect many species [61]. According to a recent
254 study, these bacteriophages may be useful in healing septic wounds caused by *P. aeruginosa*,
255 *S. aureus*, *K. pneumoniae*, and *E. coli* [12]. When utilized in a bacteriophage cocktail, these
256 phages could be a promising first-line treatment for wound sepsis, with the added benefit of
257 not enhancing multidrug resistance in bacteria and being able to function concurrently on a
258 wide variety of MDR bacteria. Before this approach may be used therapeutically, additional
259 regular standardization is still required.

260 **3.1 Treatment failure and antimicrobial resistance**

261 The widespread use of antibiotics both for human consumption and animal production has
262 fostered the development of resistance in various pathogenic bacteria [63]. The rise of bacterial
263 strains resistant to several medicines, or multidrug-resistant strains, is becoming a significant
264 cause of infection treatment failure worldwide [12]. Drug-resistant germs kill 25,000 people in
265 Europe per year, whereas MDR-bacterial infections kill 23,000 people in the United States
266 every year [64]. According to WHO reports, drug resistance in bacteria has been detected in
267 all parts of the world [59]. A survey of wound infections in Mayamar, South East Asia, revealed
268 a high level of resistance with *Staphylococcus aureus* isolates resistant to penicillin (98%),
269 oxacillin (70%), and tetracycline (66%), while *Escherichia coli* showed resistance to ampicillin
270 (98%) [65]. Similarly, high resistance rates were documented in chronically infected wounds
271 in rural Ghana, comprising 29% methicillin resistance in *S. aureus* and resistance to third-
272 generation cephalosporins and fluoroquinolones in 33% and 58% of *Enterobacteriaceae*,
273 respectively [36]. The authors stressed the need for microbiological diagnostic approaches,

274 including antimicrobial resistance testing, to guide the management of patients with chronic
275 wounds in Ghana.

276 Over 98% of the isolates from SSIs were resistant to β -lactam antibiotics in a Nigerian hospital,
277 according to Akunkunmi and colleagues [31], while more than 70% of the isolates from SSIs
278 were resistant to erythromycin, fusidic acid, and tobramycin. *P. aeruginosa* was resistant to six
279 antibiotics (amoxicillin, erythromycin, cotrimoxazole, gentamycin, streptomycin, and Zinacef)
280 out of 10 employed in a study of diabetic wound infection in a rural community in Nigeria [29].
281 Vancomycin is used as a last option to treat methicillin-resistant *Staphylococcus aureus*
282 (MRSA), and enterococcal strains that no longer react to vancomycin have also been identified
283 [66]. Etok and colleagues [34] found 100% methicillin resistance in *Staphylococcus aureus*
284 isolated from surgical wound infections and extended-spectrum beta-lactamase (ESBL)
285 production in 50% of Gram-negative isolates (*Proteus* spp., *E. coli*, and *Klebsiella* spp.) that
286 were most sensitive to imipenem. Similarly, Iroegbu et al. [22] discovered that, except for *E.*
287 *coli*, which showed significant sensitivity to amoxicillin/clavulanate (83%) and *S. aureus* to
288 erythromycin (79%) and chloramphenicol (100%), all common isolates were more than 30%
289 resistant to all commonly used first-line drugs, particularly third-generation cephalosporins and
290 gentamycin. Mechanisms of bacteria resistance to antibiotics fall into three main categories:
291 antibiotic deactivation by modification of its active chemical moiety; the specific modification
292 of the macromolecular target by mutagenesis of key residues; the prevention of antibiotics from
293 reaching their targets through decreased uptake [67]. The growth and spread of ESBL among
294 Gram-negative bacteria is a major challenge when trying to control wound infections and
295 hospital costs. In Gram-negative bacteria isolated from orthopedic wound infections in Ile-Ife,
296 Nigeria, Idowu et al. [68] found a 35% ESBL incidence. Of the 102 Gram-negative bacteria
297 isolated, 36 were positive for ESBL, mainly of the Enterobacteriaceae family. They also
298 discovered that the ESBL gene was horizontally transmitted, as were the genes for tetracycline,
299 cotrimoxazole, nitrofurantoin, gentamicin, and aztreonam resistance. Almost all of the bacteria
300 identified from SSIs were resistant to routinely administered antibiotics such as ampicillin,
301 cotrimoxazole, streptomycin, and tetracycline, according to a study by Mofikoya and
302 colleagues [30]. In nearly 80% of the infected individuals, the cultured aerobes showed less
303 than 50% sensitivity to the cephalosporins examined (ceftazidime, cefuroxime, and
304 ceftriaxone). With this level of antibiotic resistance, choosing an empirical treatment becomes
305 extremely difficult.

306 **3.2 Effects of Biofilm formation on wound management**

307 One of the most critical components of wound care is identifying and treating biofilms.
308 Biofilms are formed when single-cell bacteria attach to the exposed extracellular matrix
309 proteins on the wound surface [69,70]. Wound biofilms are bound together by extracellular
310 polymeric substrates attached to the surface, making them resistant to external forces that might
311 otherwise overwhelm a single bacterium [69]. Biofilms can contribute to bacterial infection,
312 inflammation, and delayed wound healing [71], which can considerably influence wound
313 healing. Because of these concerns, reduced biofilm presence is an important component of
314 good wound care. Biofilms were discovered in 60% of chronic wounds and just 6% of acute
315 wounds, according to James and workers [72], who examined materials from 50 chronic
316 wounds and 16 acute wounds. According to this study, chronic wounds have more substantial
317 evidence of biofilms than acute wounds. Kirketerp-Moller and colleagues [73] examined
318 wound samples from 22 individuals who were suspected of having *P. aeruginosa* infection.
319 They discovered that *P. aeruginosa* was present in these wounds as biofilms rather than single
320 cells using PNA FISH and anti-alginate antibodies. Although it may be tempting for the
321 physician to begin antibiotic therapy, in the event of an established, mature biofilm, this
322 treatment will most likely only have a transient effect on both inflammation and healing.
323 Furthermore, the doctor must rely on swab or biopsy data, which rarely accurately represent all
324 bacteria species present in the wound. Antibiotics have a lower efficacy against bacteria in
325 biofilms [74,75]. According to Neopane et al., the Minimum Inhibitory Concentration (MIC)
326 is not achieved in chronic wound fluid. Biofilm development was found in 30 (69.8%) and 28
327 (65.1%) isolates of *S. aureus* from wounds of hospitalized patients, respectively, using tissue
328 culture plates and tube adherence methods [75]. In this study, biofilm-producing *S. aureus* had
329 a greater rate of antimicrobial resistance than biofilm nonproducers, with 86.7% of biofilm-
330 producing *S. aureus* being multidrug-resistant. In light of this, the practitioner should use
331 caution when prescribing antibiotics. Antibiotic administration favors microorganisms that
332 may form biofilms and promote antibiotic resistance. Mechanical removal of wound waste,
333 including granulation tissue, is an effective method for reducing bacterial load.

334

335 **4. ROLE OF THE MICROBIOLOGY LABORATORY IN GUIDING ANTIBIOTIC** 336 **TREATMENT**

337 Due to the complex etiology of wound infections, empirical therapy is not usually advisable.
338 Microbiological data are critical in validating the appropriateness of a treatment plan in a
339 quickly spreading soft tissue illness. Most doctors give broad-spectrum antimicrobial
340 medicines before evaluating a microbiology report in chronic wounds that have failed to heal.

341 In many cases, the therapy is incorrect or unnecessary, resulting in a more extended stay in the
342 hospital and the emergence of resistant strains. Furthermore, broad-spectrum antibiotics might
343 disrupt normal gut microbiota, potentially putting patients at risk for *Clostridium difficile* colitis
344 and other opportunistic infections (e.g., vancomycin-resistant *Enterococcus*) [76]. It is crucial
345 to identify the clinically relevant isolates, undertake antibiotic susceptibility testing, and then
346 provide guidance on the most appropriate treatment based on information acquired about the
347 location of wound infection and clinical symptoms [77,78]. This support will aid in not only
348 good wound treatment but also the control of antibiotic usage, reducing the spread of antibiotic-
349 resistant germs.

350 In addition, the microbiology laboratory is critical in monitoring antibiotic resistance in wound
351 infections. Laboratory-based surveillance is recommended as a preliminary step toward
352 monitoring resistance trends to prevent further development and spread of drug resistance,
353 according to the WHO global action plan to combat the growing problem of resistance to
354 antibiotics and other antimicrobial medicines [18].

355

356 **5.0 CONCLUSION**

357 Although the microbiology of wounds has received much attention in recent years, there is still
358 a lot to learn about the microbial pathways that cause infection and hinder wound healing.
359 Clinical microbiology laboratories should create local reproducible, standardized
360 methodologies to evaluate wound bacterial isolates for antimicrobial susceptibility regularly.
361 Uniform adherence to the existing WHO recommendations for wound infection prevention and
362 care will also help to reduce wound infections significantly. According to research, most open
363 wounds are polymicrobial, with anaerobic bacteria accounting for one-third of all microbial
364 species in colonized wounds. As a result, antimicrobial therapy of clinically infected wounds
365 should cover potentially synergistic aerobic, facultative, and anaerobic microbes rather than
366 focusing on a few pathogens that are frequently thought to be the cause. The use of
367 metronidazole for the treatment of anaerobic infections is recommended.

368 **Authors' contributions**

369 The participation of each author corresponds to the criteria of authorship and contributorship
370 emphasized in the Recommendations for the Conduct, Reporting, Editing, and Publication of
371 Scholarly work in Medical Journals of the International Committee of Medical Journal Editors.
372 Indeed, all the authors have actively participated in the redaction, the revision of the
373 manuscript, and provided approval for this final revised version.

374

375 **Acknowledgements**

376 None.

377

378 **Funding**

379 None

380

381 **Conflict of interest**

382 The authors declare that there is no conflict of interest regarding the publication of this article.

383

384

385

386 **References**

- 387 1. World Health Organisation (2011). Report on the burden of endemic health care-associated infection
388 worldwide. Geneva: World Health Organization, 2011.
389 http://apps.who.int/iris/bitstream/10665/80135/1/9789241501507_eng.pdf (accessed Oct 9, 2016).
- 390 2. Allegranzi, B., Bagheri, N. S., Combescure, C., *et al.* (2011). Burden of endemic health-care-associated
391 infection in developing countries: systematic review and meta-analysis. *Lancet*; 377: 228–41.
- 392 3. European Center for Disease Control (2013). Point prevalence survey of healthcare-associated infections
393 and antimicrobial use in European acute care hospitals. Stockholm: European Centre for Disease Prevention
394 and Control, 2013. [http://ecdc.europa.eu/en/publications/Publications/healthcare-associated-infections-
395 antimicrobial-use-PPS.pdf](http://ecdc.europa.eu/en/publications/Publications/healthcare-associated-infections-antimicrobial-use-PPS.pdf)
- 396 4. Magill, S.S., Edwards, J.R., Bamberg, W., *et al.* (2014). Multistate point-prevalence survey of health care-
397 associated infections. *N Engl J Med*; 370: 1198–208.
- 398 5. Amoran, O.E., Sogebi, A.O., Fatugase, O.M. (2013). Rates and Risk Factors Associated with Surgical Site
399 Infection in a Tertiary Care Center in South-West Nigeria. *International Journal of Tropical Disease and
400 Health*. 3(1): 25-36.
- 401 6. Abubakar, I., Maikaje, D.B., Orukotan, A.A., Gana, E.N., and Ibrahim, H.A. (2018). Characterization and
402 Antibiogram of Bacteria Isolated from Surgical Wounds of Patients Attending Ibrahim Badamasi Babangida
403 Specialist Hospital Minna, Niger State, Nigeria. *Journal of Advances in Microbiology* 9(1): 1-9.
- 404 7. Olowo-okere, A., Ibrahim, Y. K. E., Sani, A. S. and Olayinka, B. O. (2018). Occurrence of Surgical Site
405 Infections at a Tertiary Healthcare Facility in Abuja, Nigeria: A Prospective Observational Study. *Med. Sci.*
406 6, 60
- 407 8. Taiwo, S.S., Okesina, A.B., Onile, B.A. (2002). Invitro antimicrobial susceptibility pattern of bacterial
408 isolates from wound infection in university of Ilorin Teaching Hospital *Afr J Clin Exp Microbiol*. 3(1): 6-
409 10.
- 410 9. Azzopardi, E.A., Azzopardi, E., Camilleri, L., Villapalos, J., Boyce, D.E., *et al.* (2014) Gram Negative
411 Wound Infection in Hospitalised Adult Burn Patients- Systematic Review and Metanalysis-. *PLoS ONE*
412 9(4): e95042. doi:10.1371/journal.pone.0095042
- 413 10. Van Delden, C., Iglewski, B.H. (1998). Cell-to-cell signaling and *Pseudomonas aeruginosa* infections.
414 *Emerg. Infect. Dis*. 4:551–560.
- 415 11. Dionigi, R., Rovera, F., Dionigi, G., Imperatori, A., Ferrari, A., Dionigi, P., Dominion, I. (2001).Risk factors
416 in Surgery. *J. Chemother*. 13: 6-11.
- 417 12. Pallavali, R.R., Degati, V.L., Lomada, D., Reddy, M.C., Durbaka, V.R.P. (2017) Isolation and *in vitro*
418 evaluation of bacteriophages against MDR- bacterial isolates from septic wound infections. *PLoS ONE*
419 12(7): e0179245. <https://doi.org/10.1371/journal.pone.0179245>
- 420 13. Gottrup, F. (2004). A specialized wound-healing center concept: importance of a multidisciplinary
421 department structure and surgical treatment facilities in the treatment of chronic wounds. *Am J Surg*.
422 187(5A):38S–43S.
- 423 14. Diabetes Atlas (2012). International Diabetes Federation. The IDF Diabetes Atlas. 5th edition. A summary
424 of the figures and key findings. www.idf.org/diabetesatlas/papers.
- 425 15. Bowler, P., Duerden, B., Armstrong, D. (2001). Wound microbiology and associated approaches to wound
426 management. *Clin Microbiol Rev*. 14: 2, 244-269.
- 427 16. Sawdekar, H., Sawdekar, R., Wasnik, V.R. (2015). Antimicrobial susceptibility pattern of bacterial isolates
428 from wound infection and their sensitivity to antibiotic agents at super specialty hospital, Amravati city,
429 India *Int J Res Med Sci*; 3(2):433-439
- 430 17. Shittu, A.O., Kolawole, D.O., Oyedepo, E.R. (2002). A study of wound infections in two health institutions
431 in Ile-Ife, Nigeria. *Afr. J. Biomed. Res*. 5: 97-10.
- 432 18. World Health Organization. Surveillance standards for antimicrobial resistance (2016). Available from:
433 <http://www.who.int/csr/resources/publications/drugresist/whocdscsrdrs20015>.
- 434 19. Nasir, I.A., Babyo, A., Emeribe, A.U., and Sani, N.O. (2015). Surveillance for Antibiotic Resistance in
435 Nigeria: Challenges and Possible Solutions. *Trends in Medical Research* 10 (4): 106-113, 2015

- 436 20. Kooistra-Smid, M., Nieuwenhuis, M., van Belkum, A., Verbrugh, H. (2009). The role of nasal carriage in
437 Staphylococcus aureus burn wound colonization. *FEMS Immunol Med Microbiol.* 57: 1-3.
- 438 21. Akinjogunla, O.J., Adegoke, A.A., Mboti, C.I., Chukwudebelu, I.C., Udokang, I.P. (2009), Bacteriology of
439 automobile accident wounds infection. *International Journal of Medicine and Medical Sciences.* 1(2): 023-
440 027.
- 441 22. Iregbu, K.C., Uwaezuoke, N.S., Nwajiobi-Princewell, I.P., Eze, S.O., Medugu, N., Shettima, S., Modibbo,
442 Z. (2013). A profile of wound infections in National Hospital Abuja. *Afr J Clin Exp Microbiol.* 4(3): 160-
443 163.
- 444 23. Saini S., Gupta N., Lokveer A., Griwan M.S. (2004). Surgical Infections: A Microbiological Study. *The*
445 *Brazilian J Infect Dis.* 8(2): 118-125. Bowler and Davies, 1999.
- 446 24. Bowler, P.G., Davies, B.J. (1999) The microbiology of infected and noninfected leg ulcers. *Int J Dermatol.*
447 38: 573-578.
- 448 25. Gethin, G., Cowman, P.S. (2008). Bacteriological changes in sloughy venous leg ulcers treated with manuka
449 honey or hydrogel: an RCT. *J Wound Care.* 17: 241-247.
- 450 26. Allegranzi, B., Bischoff, P., de Jonge, S., Kubilay, N. Z., Zayed, B., Gomes, S. M., Abbas, M., Atema, J. J.,
451 Gans, S., van Rijen, M., Boermeester, M. A., Egger, M., Kluytmans, J., Pittet, D., Solomkin, J. S. and the
452 WHO Guidelines Development Group (2016). New WHO recommendations on preoperative measures for
453 surgical site infection prevention: an evidence-based global perspective. *Lancet Infect Dis*
454 [http://dx.doi.org/10.1016/S1473-3099\(16\)30398-X](http://dx.doi.org/10.1016/S1473-3099(16)30398-X)
- 455 27. Allegranzi, B., Bischoff, P., de Jonge, S., Kubilay, N. Z., Zayed, B., Gomes, S. M., Abbas, M., Atema, J. J.,
456 Gans, S., van Rijen, M., Boermeester, M. A., Egger, M., Kluytmans, J., Pittet, D., Solomkin, J. S. and the
457 WHO Guidelines Development Group (2016b) New WHO recommendations on intraoperative and
458 postoperative measures for surgical site infection prevention: an evidence-based global perspective. *Lancet*
459 *Infect Dis* 2016 [http://dx.doi.org/10.1016/S1473-3099\(16\)30398-X](http://dx.doi.org/10.1016/S1473-3099(16)30398-X)
- 460 28. Berríos-Torres, S. I., Umscheid, C. A., Bratzler, D.W., Leas, B., Stone, E. C., Kelz, R. R., Reinke, C. E., et
461 al. (2017).. Guideline for the Prevention of Surgical Site Infection, Centers for Disease Control and
462 Prevention for the Healthcare Infection Control Practices Advisory Committee. *JAMA Surg.*
463 2017;152(8):784-791.
- 464 29. Osariemen, I.J., Olowu, S.S., Adevbo, E., Omon, E.E., Victoria, O., Imuetinyan, E.J., Adesuwa, E. (2013).
465 Aerobic Bacteria Associated With Diabetic Wounds In Patients Attending Clinic In A Rural Community In
466 Nigeria. *Global Res J Microbiol.* 3(1): 8 – 12.
- 467 30. Mofikoya, B.O., Neimogha, M.I., Ogunsola, F.T., Atoyebi, O.A. (2009). Bacterial Agent of Abdominal Site
468 Infections in Lagos, Nigeria. *European Journal of Scientific Research.* 38(3): 509-513.
- 469 31. Akinkunmi, E. O., Adesunkanmi, A, Lamikanra, A. (2014). Pattern of pathogens from surgical wound
470 infections in a Nigerian hospital and their antimicrobial susceptibility profiles. *African Health Sciences;*
471 14(4): 802-809.
- 472 32. Mordi, R.M., Momoh, M.I. (2009). Incidence of *Proteus* species in wound infections and their sensitivity
473 pattern in the University of Benin Teaching Hospital. *Afr J Biotech.* 8(5): 725-730.
- 474 33. Mahdi, S.E.I., Ahmed, A.O.A., Boelens, H., Ott, A., Abugroun, E.S., van Belkum, A., Zijlstra, E, Verbrugh,
475 H, Fahal, A (2000). An epidemiological study of the occurrence of Staphylococcus aureus in superficial
476 abscesses of patients presenting for surgery in a teaching hospital in Khartoum, Sudan. *FEMS Immunology*
477 *and Medical Microbiology.* 29: 155-162.
- 478 34. Etok, C.A., Edem, E.N., Ochang, E. (2012). Aetiology and antimicrobial studies of surgical wound infections
479 in University of Uyo Teaching Hospital (UUTH) Uyo, Akwa Ibom State, Nigeria. *Open Access Scientific*
480 *Reports.* 1(7): 341.
- 481 35. Kehinde, A.O., Ademola, S.A., Okesola, A.O., Oluwatosin, O.M., Bakare, R.A. (2004). Pattern of bacterial
482 pathogens in burn wound infections in Ibadan Nigeria. *Ann. Burns Fire Disasters.* 17(1): 12-15.
- 483 36. Krumkamp, R., Oppong, K., Hogan, B., Strauss, R., Frickmann, H., Wiafe-Aktenen, C., et al. (2020)
484 Spectrum of antibiotic resistant bacteria and fungi isolated from chronically infected wounds in a rural
485 district hospital in Ghana. *PLoS ONE* 15(8): e0237263. <https://doi.org/10.1371/journal.pone.0237263>
- 486 37. Vicar, E.K., Acquah, S.E.K., Williams, W., Kuugbee, E.D., Saba, C.K.S., and Mensah, G.I. (2021).
487 Antibiotic Resistant Bacteria Infecting Wounds of Rural Community Dwellers in Northern Ghana. *European*
488 *Journal of Medical and Health Sciences.* 3 : 112-117; DOI: <http://dx.doi.org/10.24018/ejmed.2021.3.1.678>

- 489 38. Be, N. A., Allen, J. E., Brown, T. S., Gardner, S. N., McLoughlin, K. S., Forsberg, J. A., Kirkup, B. C.,
490 Chromy, B. A., Luciw, P. A., Elster, E. A., Jainga, C. J. (2014). Microbial Profiling of Combat Wound
491 Infection through Detection Microarray and Next-Generation Sequencing. *Journal of Clinical Microbiology*;
492 52(7): 2583–2594
- 493 39. Auwaerter, P. (2008). Antibiotic guide. Johns Hopkins ABX (antibiotic) Guide, Baltimore, MD.
- 494 40. Nwaokorie, F.O, Nwokoye, N.N., Yisau, J.A. (2011). Survey of Anaerobic Infection Diagnostic Facilities
495 in Laboratories in Nigeria. *Nig J Clin Biomed Res.* 12 (2)49-52.
- 496 41. Makanjuola, O. B., Olowe, O. A., Adeyankinnu, A. F. (2013). Bacterial Agents of Surgical Site Infections
497 in South-Western Nigeria. *Am. J. Biomed. Sci.* 2013, 5(4), 217-225
- 498 42. Abdu A.B., Egbagba J., Fente B.G. (2018). Identification and antimicrobial susceptibility profile of bacterial
499 pathogens isolated from wound infections in a tertiary hospital, Bayelsa South southern, Nigeria. *Tropical*
500 *Journal of Pathology & Microbiology.* Volume 06 – Issue 04, August 2018
- 501 43. Moro, D. D., Bello, H. O. and Akano, S. O. (2018). Incidence and Antibiotic Resistance Pattern of Bacteria
502 Associated with Wound infection in some Hospitals in Lagos, Nigeria. *Asian Journal of Applied Sciences*
503 (ISSN: 2321 – 0893) Volume 06 – Issue 04, August 2018
- 504 44. Torpy, J.M., Burke, A., Glass, R.M. (2005). Wound Infections. *JAMA.* 2005;294(16):2122.
505 doi:10.1001/jama.294.16.2122
- 506 45. Power, K., Davies, M.M., Hargest, R., Phillips, S., Torkington, J., Morris, C. (2014). A case-control study of
507 risk factors for wound infection in a colorectal unit. *Ann R Coll Surg Engl*; 96: 37–40 doi
508 10.1308/003588414X13824511650137
- 509 46. Thimmappa, L., Bhat, A., Hande, M., Mukhopadhyay, C., Devi, E., Nayak, B., et al. (2021). Risk factors for
510 wound infection caused by Methicillin Resistant Staphylococcus aureus among hospitalized patients: a case
511 control study from a tertiary care hospital in India. *Afri Health Sci.* 2021;21(1):286-94.
512 <https://dx.doi.org/10.4314/ahs.v21i1.37>
- 513 47. Korol, E., Johnston, K., Waser, N., Sifakis, F., Jafri, H.S., et al. (2013) A Systematic Review of Risk Factors
514 Associated with Surgical Site Infections among Surgical Patients. *PLoS ONE* 8(12): e83743.
515 doi:10.1371/journal.pone.0083743
- 516 48. Kihla, A.J., Ngunde, P.J., Evelyn, M.S., Gerard, O N., Ndip, R.N. (2014). Risk factors for wound infection in
517 health care facilities in Buea, Cameroon: aerobic bacterial pathogens and antibiogram of isolates. *Pan Afr*
518 *Med J.* 2;18:6. doi: 10.11604/pamj.2014.18.6.2304.
- 519 49. Schlager, J.G., Hartmann, D., Wallmichrath, J., et al. (2022). Patient dependent risk factors for wound
520 infection after skin surgery: A systematic review and meta-analysis. *Int Wound J.* 2022;1-10.
521 doi:10.1111/iwj.13780
- 522 50. Nwankwo, E.O., Ibeh, I.N., Enabulele, O.I. (2012). Incidence and risk factors of surgical site infection in a
523 tertiary health institution in Kano, Northwestern Nigeria. *Int J Infect Control*, v8:i4 doi
- 524 51. Rabiou, K.A., Akinlusi, F.M., Adewunmi, A.A., Alausa, T.G., Durojaiye, I.A. (2020). Risk factors for
525 postcesarean wound infection in a tertiary hospital in Lagos, Nigeria. *Niger Med J*; 61:262-8.
- 526 52. White, R., Cooper, R., Kingsley, A. (2001). Wound colonization and infection. *B J Nurs.* 10: 563-578.
- 527 53. World Health Organization (2013). Prevention and management of wound infection. Guidance from WHO's
528 Department of Violence and Injury Prevention and Disability and the Department of Essential Health.
529 Technologies.
530 https://www.who.int/hac/techguidance/tools/guidelines_prevention_and_management_wound_infection.pdf
531 f
- 532 54. Kalmeijer, M.D., Coertjens, H., van Nieuwland-Bollen, P.M., Bogaers-Hofman, D., de Baere, G.A.,
533 Stuurman, A., et al (2002). Surgical site infections in orthopedic surgery: the effect of mupirocin nasal
534 ointment in a double-blind, randomized, placebo-controlled study. *Clin Infect Dis.* 35:353–358.
- 535 55. Sani R. A., Garba S. A., Oyewole O. A., Ibrahim A. (2012). Antibiotic Resistance Profile of Gram-Positive
536 Bacteria Isolated from Wound Infections in Minna, Bida, Kontagora and Suleja Area of Niger State. *Journal*
537 *of Health Sciences*, 2(3): 19-22
- 538 56. Kalita, S., Devi, B., Kandimalla, R., Sharma, K. K., Sharma, A., Kalita, K., Katak, A. C., Kotoky, J. (2015).
539 Chloramphenicol encapsulated in poly-ε-caprolactone-pluronic composite: nanoparticles for treatment of
540 MRSA-infected burn wounds. *International Journal of Nanomedicine*; 10 2971–2984
- 541 57. Heal, C F., Buettner, P. G., Cruickshank, R., Graham, D., Browning, S., Pendergast, J., Drobotz, H., Gluer,
542 R., Lisec C. (2009). Does single application of topical chloramphenicol to high risk sutured wounds reduce

543 incidence of wound infection after minor surgery? Prospective randomised placebo controlled double blind
544 trial. *BMJ* 2009;338:a2812 doi:10.1136/bmj.a2812

545 58. McHugh1, S. M., Collins, C. J., Corrigan, M. A., Hill, A. D. K., and Humphreys, H. (2011). The role of
546 topical antibiotics used as prophylaxis in surgical site infection prevention. *J Antimicrob Chemother*; 66:
547 693–701

548 59. WH Organization (2014) Antimicrobial resistance global report on surveillance: 2014 summary.

549 60. Wang Z, Zheng P, Ji W, Fu Q, Wang H (2016) SLPW: A Virulent Bacteriophage Targeting Methicillin-
550 Resistant *Staphylococcus aureus* In Vitro and In Vivo. *Frontiers in Microbiology* 7: 934. [https://doi.org/](https://doi.org/10.3389/fmicb.2016.00934)
551 10.3389/fmicb.2016.00934

552 61. Haq IU, Chaudhry WN, Akhtar MN, Andleeb S, Qadri I (2012) Bacteriophages and their implications on
553 future biotechnology: a review. *Virology Journal* 9: 1.

554 62. Jido, TA, Garba, ID (2013). Surgical-site Infection Following Cesarean Section in Kano, Nigeria. *Annals of*
555 *Medical and Health Sciences Research*. 2(1): 33-36.

556 63. Dessen, A, Mouz, N, Gordon, E, Hopkins, J, Dideberg, O (2001). Crystal structure of PBP2x from a highly
557 penicillin-resistant *Streptococcus pneumonia* clinical isolate. *Journal of Biological Chemistry*. 45 (2): 106-
558 121.

559 64. World Health Organization. Surveillance standards for antimicrobial resistance (2016). Available from:
560 [http:// www.who.int/csr/resources/publications/drugresist/whodscsrdrs20015](http://www.who.int/csr/resources/publications/drugresist/whodscsrdrs20015).

561 65. Sandar, W.P.; Saw, S.; Kumar, A.M.V.; Camara, B.S.; Sein, M.-M. (2021). Wounds, Antimicrobial
562 Resistance and Challenges of Implementing a Surveillance System in Myanmar: A Mixed-Methods Study.
563 *Trop. Med. Infect. Dis.* 2021, 6, 80. <https://doi.org/10.3390/tropicalmed6020080>

564 66. Novak, R, Henriques, B, Charpentier, E, Normark, S, Tuomanen, E (1999). Emergence of Vancomycin
565 tolerance in *Streptococcus pneumonia*, *Nature*. 399 (6736): 590-593.

566 67. Walsh, C (2000). Molecular mechanisms that confer antibacterial drug resistance. *Nature*. 406(23): 775-781.

567 68. Idowu, O.J., Onipede, A. O., Orimolade, A. E., Akinyoola, L. A., and Babalola, G. O. (2011). Extended-
568 spectrum Beta-lactamase Orthopedic Wound Infections in Nigeria. *J Glob Infect Dis*. 3(3): 211–215.

569 69. Wolcott, R, Rhoads, D, Dowd, S (2008). Biofilms and chronic wound inflammation. *J Wound Care*. 17: (8)
570 333-341.

571 70. Clinton, A., Carter, T. (2015). Chronic Wound Biofilms: Pathogenesis and Potential Therapies; *Lab*
572 *Medicine* 46 (4): 277-284.

573 71. Phillips, P.L., Wolcott, R.D., Fletcher, J., Schultz, G.S. (2010). Biofilms made easy. *Wounds Int.*;1(3).

574 72. James, GA, Swogger, E, Wolcott, R, Pulcini, E, Secor, P, Sestrich, J, Costerton, JW, Stewart, PS (2008).
575 Biofilms in chronic wounds. *Wound Repair Regen*. 16(1):37–44.

576 73. Kirketerp-Moller, K, Jensen, PO, Fazli, M, Madsen, KG, Pedersen, J, Moser, C, Tolker-Nielsen, T, Hoiby,
577 N, Givskov, M, Bjarnsholt, T (2008). Distribution, organization, and ecology of bacteria in chronic wounds.
578 *J Clin Microbiol*. 46(8):2717–2722.

579 74. Bjarnsholt T, Kirketerp-Moller K, Jensen PO, Madsen KG, Phipps R, Krogfelt K, Hoiby N, GivskovM
580 (2008). Why chronic wounds will not heal: a novel hypothesis. *Wound Repair Regen*. 16(1):2–10.

581 75. Neopane, P., Nepal, H. P., Shrestha, R., Uehara, O., Abiko, Y. (2018). In vitro biofilm formation by
582 *Staphylococcus aureus* isolated from wounds of hospital-admitted patients and their association with
583 antimicrobial resistance. *International Journal of General Medicine* 2018:11 25–32

584 76. Papasian, C.J., Kragel, PJ (1997). The microbiology laboratory’s role in life-threatening infections. *Crit.*
585 *Care Nurs. Q.* 20:44–59.

586 77. Washington, J.A. (1999). The role of the microbiology laboratory in antimicrobial susceptibility testing.
587 *Infect. Med.* 16:531–532.

588 78. Clinical and Laboratory Standards Institute (2018). Performance Standards for Antimicrobial Susceptibility
589 Testing, 28th ed. CLSI supplement M100 (ISBN 1-56238-838-X [Print]; ISBN 1-56238-839-8 [Electronic]).
590 Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087
591 USA, 2018

Table 1: Bacteriological profile of infected wounds in Nigeria

| Location | Study description and no. of wounds | No. of microbial isolates | Predominant isolates in descending order of frequency | References |
|------------|---|---------------------------|---|------------|
| Uyo | Analysis of purulent materials from 40 patients with automobile accident wounds | 74 | <i>Staphylococcus aureus</i> (37.8%), <i>Pseudomonas aeruginosa</i> (27.0%), <i>Escherichia coli</i> (14.9%), <i>Streptococcus pyogenes</i> (12.2%), and <i>Klebsiella pneumoniae</i> (8.11%) | 21 |
| Abeokuta | 200 samples from surgical sites | 160 | <i>Staphylococcus aureus</i> (28.75%), <i>Pseudomonas aeruginosa</i> (16.25%); <i>Proteus species</i> (11.25%), <i>Klebsiella species</i> (8.75%), <i>Enterococcus species</i> (1.25%), and α -hemolytic streptococci (1.25%) | 41 |
| Minna | 50 swab samples of infected surgical wound | 30 | <i>Staphylococcus aureus</i> (46.67%), <i>Pseudomonas aeruginosa</i> (20%), <i>Streptococcus agalactiae</i> (10%), <i>Streptococcus pyogenes</i> (10%), <i>Escherichia coli</i> (6.67%), <i>Clostridium perfringens</i> (3.33%), and <i>Klebsiella ozaenae</i> (3.33%) | 6 |
| Bayelsa | 130 wound samples were using Sterile Swab Sticks | 164 | Aerobes: <i>Pseudomonas aeruginosa</i> (28, 17.07%), followed by <i>E. coli</i> (19, 11.58%), <i>Klebsiella pneumoniae</i> (17, 10.37%), <i>Staphylococcus aureus</i> (10, 6.10%) Anaerobes: <i>Bacteroides fragilis</i> (16, 9.75%), <i>Peptostreptococcus</i> spp. (2.44%), and <i>Prevotella</i> spp. (2.44%) | 42 |
| Benin City | Analysis of 400 wound swab samples from many sites | 560 | <i>Staphylococcus aureus</i> (30%), <i>Proteus</i> spp. (26.8%), <i>Pseudomonas species</i> (23.6%), <i>E. coli</i> (11.6%), <i>Klebsiella species</i> (6.61%), <i>Streptococcus species</i> (0.8%), <i>Providencia species</i> (0.5%), and <i>Enterobacter species</i> (0.36%) | 32 |
| Ile-Ife | 102 swab samples from many wound sites | 162 | <i>Staphylococcus aureus</i> (25%), <i>Escherichia coli</i> (12%), <i>Pseudomonas aeruginosa</i> (9%), and <i>Staphylococcus epidermidis</i> (9%) | 17 |
| Lagos | 144 swab samples of surgical wounds were analyzed | 14 | Aerobes: <i>P. aeruginosa</i> , <i>Enterobacter</i> spp., <i>Proteus</i> spp., and <i>Klebsiella</i> spp. Anaerobes: <i>Bacteroides</i> spp., <i>Eubacterium</i> spp., and <i>Actinomyces</i> spp. | 30 |
| Lagos | 202 wound samples consisting of surgical, burn, and accident/cut | 320 | <i>Pseudomonas aeruginosa</i> , (128, 40%), <i>Enterobacter</i> spp., (60, 19%), <i>Proteus mirabilis</i> (56, 18%), <i>Escherichia coli</i> , (20, 6%) and <i>Staphylococcus aureus</i> (16, 5%) | 43 |

| | | | | |
|---------|--|-----|--|----|
| Edo | 150 wound swabs from diabetic patients were analyzed | 50 | <i>Staphylococcus aureus</i> (38%), <i>Escherichia coli</i> (24%), <i>Proteus</i> spp. (20%), <i>Klebsiella</i> spp (10%), and <i>Pseudomonas aeruginosa</i> (8%) | 29 |
| Uyo | Analysis of 120 infected surgical wounds | 150 | <i>Proteus</i> spp. (33.3%), <i>Staphylococcus aureus</i> (20.0%), <i>Escherichia coli</i> (20.0%), <i>Coagulase-negative Staphylococcus</i> (13.3%), <i>Klebsiella</i> spp. (6.7%), and <i>Pseudomonas</i> spp. (6.7%) | 34 |
| Sagamu | 50 surgical site infections were analyzed | 49 | <i>E. coli</i> (34.7), <i>S. aureus</i> (32.7%), <i>Proteus mirabilis</i> (14.3), and <i>Klebsiella</i> spp. (18.4%) | 5 |
| Abuja | 380 wound specimens from various sites | 314 | <i>S. aureus</i> (27%), <i>P. aeruginosa</i> (19%), <i>E. coli</i> (14%), <i>K. pneumoniae</i> (13%), <i>Proteus</i> spp. (18%) | 22 |
| Ile-Ife | 89 surgical site wound samples | 126 | <i>S. aureus</i> (18.3%) <i>P. aeruginosa</i> and <i>Bacillus</i> spp. (11.1% each), <i>E. coli</i> (10.3%), <i>Coagulase-negative Staphylococci</i> (8.7%), <i>Pseudomonas</i> spp. (6.3%), <i>Serratia odorifera</i> (4.7%), <i>Bacteroides</i> (4.0%), and <i>Enterococcus</i> spp. (3.2%) | 31 |

595
596
597

Table 2: Bacterial isolates from wound infections in Nigeria and their susceptibility pattern to commonly used antibiotics.

| Site | Bacterial isolates | Susceptibility | References |
|--|---|---|------------|
| Diabetic wounds | <i>S. aureus</i> , <i>E.coli</i> , <i>Proteus</i> spp., <i>Klebsiella</i> spp., <i>P. aeruginosa</i> | Sensitive to Pefloxacin, Augmentin, Rocephin/ Zinacef, Ciprofloxacin, and Gentamycin Resistant to Erythromycin and Cotrimoxazole | 29 |
| Multiple sites (trauma, pathological, and postoperative wound) | <i>S.aureus</i> , <i>Proteus</i> spp., <i>Pseudomonas</i> spp., <i>E.coli</i> , <i>Klebsiella</i> spp., <i>Streptococcus</i> spp. | Sensitive to Ofloxacin, Ciprofloxacin and Gentamycin Resistant to Erythromycin and Tetracycline | 32 |
| Surgical site infection following Cesarean section | <i>S. aureus</i> , <i>E. coli</i> , <i>Pseudomonas</i> spp., <i>Salmonella</i> spp., <i>Morganella morganii</i> | Sensitive to second and third-generation Cephalosporins, Quinolones, Amoxicillin-clavulanate, and Macrolides | 62 |
| Automobile accident wound | <i>S. aureus</i> , <i>Pseudomonas aeruginosa</i> , <i>E.coli</i> , <i>Streptococcus pyogenes</i> , <i>Klebsiella pneumonia</i> | Sensitive to Ofloxacin, Ciprofloxacin and Pefloxacin Moderately sensitive to Augmentin and Nalidixic acid Resistant to Penicillin, Streptomycin, and Gentamycin | 21 |
| Surgical wounds | <i>Proteus</i> spp., <i>S.aureus</i> , <i>E. coli</i> , Coagulase-negative <i>Staphylococcus</i> , <i>Klebsiella</i> spp., <i>Pseudomonas</i> spp. | Gram-negative isolates: Sensitive to Imipenem and Gentamycin Resistant to Cefotaxime, Cefpodoxime, and Levofloxacin Gram-positive isolates: Sensitive to Clindamycin, Erythromycin, and Ceftriaxone Resistant to Methicillin | 34 |

598